Trials / Completed
CompletedNCT03963947
Study to Assess the Safety and Effectiveness of Beltavac® Polymerized With House Dust Mites
Observational Prospective Study to Assess the Safety and Effectiveness of Beltavac® Polymerized With House Dust Mites
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 97 (actual)
- Sponsor
- Alfons Malet i Casajuana · Academic / Other
- Sex
- All
- Age
- 3 Years – 11 Years
- Healthy volunteers
- Not accepted
Summary
Non-interventional Study to Assess the Safety and Effectiveness Profile of a SCIT Therapy With Beltavac® Polymerised With House Dust Mite in pediatric allergic patients
Detailed description
This prospective open multi-center non-interventional study assess the safety and effectiveness profile of the subcutaneous allergen-specific immunotherapy with Beltavac polymerized with house dust mite pediatric allergic patients in routine medical care. Patients receive a rush schedule administration every month for a year. They attend at least 5 study visits to inform about the adverse reactions, the self reported symptoms and the medication intake.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Beltavac® Polymerized with house dust mites | Adminstration of Beltavac® Polymerized with house dust mites according to the routine clinical practice |
Timeline
- Start date
- 2019-06-01
- Primary completion
- 2023-05-24
- Completion
- 2023-05-24
- First posted
- 2019-05-28
- Last updated
- 2023-05-25
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT03963947. Inclusion in this directory is not an endorsement.